According to the latest report by IMARC Group, titled “Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” the global cervical cancer diagnostics market reached a value of US$ 7.1 Billion in 2021. Cervical cancer refers to a type of cancer that occurs in the cervix, the lower part of the uterus. There are two main types of cervical cancer, namely adenocarcinoma and squamous cell carcinoma. Cervical cancer diagnosis is performed through various advanced laboratory tests, tools and procedures to evaluate abnormal cells and strains of human papillomavirus (HPV). These tests and procedures include conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. These procedures are followed by blood tests, body computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to determine the progress of the disease.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Cervical Cancer Diagnostics Market Trends:
The rising prevalence of sexually transmitted infections (STIs) is one of the key factors driving the global cervical cancer diagnostics market growth. Other than this, the growing adoption of advanced diagnostic procedures for the early detection of cervical cancer, along with various awareness campaigns organized by government and non-government entities, is also contributing to the market growth. In line with this, there is a growing consciousness regarding the availability of effective treatment and diagnosis methods, which is further contributing to the market growth. Leading players are developing home-based HPV testing kits to offer convenience to consumers, which is acting as another major growth-inducing factor. Additionally, the escalating demand for minimally invasive screening procedures is supporting the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is creating a positive outlook for the market. Looking forward, the market is expected to grow at a CAGR of 5.57% during 2022-2027.
- On the basis of the test type, the market has been classified into pap testing, HPV testing, cervical biopsies, colposcopy and others.
- Based on the age group, the market has been bifurcated into 20 to 35 years and above 35 years.
- On a regional basis, the market has been spread across North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Follow us on twitter : @imarcglobal